| ITUOZO FRESENIUS KABI DEUTSCHLAND GMBH
2075669 27 Aug 2020 | on 17 Aug 2022 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment of Rheumatoid arthritis (RA), Polyarticular juvenile idiopathic arthritis (pJIA), Systemic juvenile idiopathic arthritis (sJIA), Still's disease, autoimmune diseases, Giant cell arthritis (GCA), CAR T-cell induced cytokine release syndrome, cancer, diabetes, renal failure, cardiovascular diseases, cerebrovascular diseases, respiratory diseases, hematopoietic disorders, bone diseases, systemic lupus erythematosus (SLE), Crohn disease, Castleman's disease, spinal cord injury, and multiple myeloma. | | 
